The crystal structure of human transthyretin (TTR) complexed with milrinone (2-methyl-5-cyano-3,4'-bipyridin-6( 1H)-one), a positive inotropic caFdiac agent, has been refined to R = 17.4% for 8-1.9-A resolution data. This report provides the first detailed description of protein interactions for an inotropic bipyridine agent which is an effective thyroid hormone binding competitor to transthyretin. Milrinone is bound along the 2-fold axis in the binding site with its substituted pyridone ring located deep within the channel of the two identical binding domains of the TTR tetramer. In this orientation the 5-cyano group occupies the same site as the 3"iodine in the TTR complex with 3,3'-diiodothyronine (Wojtczak, A., Luft, J., and Cody, Y.
structural results confirm computer modeling studies of milrinone structural homology with thyroxine and its TTR binding interactions and explain the effectiveness of milrinone competition for thyroxine binding to TTR. To understand the weaker binding affinity of the parent inotropic drug, amrinone (5-amino-3,4'-bipyridin-6(lH)-one), modeling studies of its TTR binding were carried out which indicate that the 5-amino group cannot participate in strong interactions with TTR and the lack of the 2-methyl further weakens amrinone binding.
Thyroid hormones are important regulators of cell growth and metabolism and also exert direct effects on many physiological functions including modulation of cardiac output and cholesterol levels. However, the specific nature of their actions still remains unclear (1). For example, the heart is a major target organ of thyroid hormones which can effect both the rate (chronotropic) and strength (inotropic) of heart contractions; specific cardiotonic actions which are independent of hormone metabolic effects. Moreover, marked cardiovascular symptoms frequently are a major manifestation of thyroid disease. These cardiac effects can be a result of thyroid hormone interactions with cardiac receptors or by an increase in metabolic rates leading indirectly to increased cardiac output ( 2) . * This work was supported by Grant DK41009 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "aduettisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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The search for analogues that can suppress or stimulate specific physiological functions has led to the synthesis of numerous thyroid hormone analogues to determine the exact nature of their thyromimetic activity (3). Characterization of the structure-function relationships among hormone analogues, both in terms of their activity and their relative binding affinities to various hormone-binding proteins, indicates the importance of specific hormone structural features with respect to thyroid hormone transport and physiological responses (3-5). Thyroid hormones can also act on other enzyme systems and produce extranuclear effects. For example, thyroid hormone has been shown to stimulate Ca2+-ATPase activity from rabbit myocardial sarcolemmal membrane preparations (6). Other data indicate that the inotropic effects of thyroid hormones are attributed, at least in part, to stimulation of myosin-associated Ca2'-ATPase ( 7 ) .
Milrinone (8) . Although milrinone is a more potent cardiotonic agent than amrinone and has a lower toxicity, they have equivalent positive inotropic and vasodilatory effects as inhibitors of phosphodiesterase 111, a CAMP-metabolizing, cGMP-sensivitive enzyme which is considered their primary site of action (9-12). However, they have been shown responsive in other systems.
Stimulation of myocardial Ca2+-ATPase activity has also been reproduced by milrinone, however, this effect is not shared by amrinone, the parent cardiotonic drug (13, 14). Because these bipyridine inotropic agents shared thyromimetic activity, their action on other thyroid responsive systems has been investigated and two other systems which show differential effects for milrinone and amrinone are the resorption of bone and binding to the serum transport protein transthyretin (TTR) (15-17). Thyroid hormones have been shown to stimulate bone turnover and directly increase calcium release from bone (15,16). Milrinone was shown to have bone resorption characteristics similar to thyroxine (T4, Fig. 
IC), while amrinone acted as an inhibitor of this process (16).
Data for transthyretin binding revealed that milrinone was an effective competitor for T4 binding to transthyretin with 61% of the inhibitory potency of T4. Amrinone, on the other hand, was less than 5% as effective (17) .
Computer modeling studies comparing the molecuIar con- formations of the thyroid hormones with the bipyridine inotropic agents suggested homology between the thyroid hormone phenolic ring and the substituted pyridone ring of milrinone (17) . In this orientation the 4-keto group of both milrinone and amrinone could overlap that of the hormone 4'-hydroxy group and could participate in similar interactions. In addition, the 5-cyano group of milrinone, which has an electronegativity similar to that of iodine, occupies the same volume as the 5'-iodine of T4. However, the 5-amino group of amrinone lacks these characteristics.
TTR, a 54-kDa tetrameric protein, is one of three serum proteins transporting thyroid hormones through the general circulation and carries about 20% of the circulating thyroxine in humans (1) . It also binds different thyroxine metabolites with varying degrees of affinity dependent upon hormone substituents (3, 4). In addition, TTR can bind a wide variety of pharmacological agents including anticonvulsants, penicillin, salicylate, steroids (18), as well as plant flavonoids (19) and cardioactive agents (17) . Recent studies have also shown that the positive inotropic bipyridine milrinone is an effective binding competitor, with about 60% of the relative binding affinity of T4 for TTR (17) .
Structural data for human native transthyretin (20) and its isomorphous crystal complexes (21) (22) (23) (24) , show that TTR is a tetramer with four identical 127 amino acid monomers. There are two independent monomers in the asymmetric unit of the crystal lattice. The monomers are assembled around a central channel such that the tetramer possesses molecular 222 symmetry. The crystallographic 2-fold axis is coincident with the channel axis and results in %fold symmetry of the hormone binding site formed by the monomers A-A' (Fig. 2) . A noncrystallographic 2-fold axis relates the independent monomers within the channel and their amino acid moieties interacting with charged residues near the channel entrance (21-23).
Comparison of TTR complexes of T., and 3,3'-diiodothyronine (3,3'-T2) revealed that 3,3'-T2 is bound deeper and with a different orientation in the channel than T4 (22).
In order to understand the mechanism of molecular recognition for thyroid hormone binding sites by competitors and to validate previous computer modeling of inotropic inhibitor binding to TTR (13, 17), we have cocrystallized milrinone with human TTR and report the results of the crystal structyre determination of TTR-milrinone complex, refined to 1.9-A resolution. Also, to understand the basis for the differentiation between milrinone and amrinone competitive binding to TTR, computer modeling studies of amrinone-TTR interactions were carried out. Crystallographic Refinement-Protein coordinates from the TTR . 3,3'-T2 complex (22) were used as a starting model. The CORELS rigid-body refinement (26) against 8-3-A resolution data was followed by the refinement of positional and isotropic thermal parameters with the PRO-LSQ least-squares procedure (27) . Both monomers forming an asymmetric unit of the structure were refined independently and no restraints utilizing a noncrystallographic 222 symmetry of the tetramer were applied. The model was verified by calculating a series of residue-deleted density maps. Electron density corresponding to milrinone was observed in both thyroid hormone binding sites Of TTR. The ligands were fit to this density at the resolution of 2.4 A, with the FRODO graphics package (28) . The complex was refined with 50% occupancy for milrinone in both sites and corresponded to the saturation of binding sites under cocrystallization conditions. The current model includes 128 water molecules added at positions of density greater than 3a on difference maps and with good hydrogenbond geometry. The least-squares refinement process for S-1.9-8, data converged resulting in a crystallographic R value of 0.173 for Table 1 . The coordinates for milrinone-TTR complex will be deposited with the Protein Data Bank.
RESULTS
The structure of the TTR-milrinone complex is isomorphous with the TTR-3,3'-Tz complex reported previously ( similar for both independent binding sites, the detailed description will be presented in terms of only one site.
There are no significant changes in the protein conformation as a result of milrinone binding, compared to native transthyretin (20) or to the 3,3'-T2 complex structure (22). The largest differences between the two independent TTR monomers were observed in the flexible loop between residues 98 and 103 of monomer B. The electron density was poorly defined and residue-deletion maps did not improve the fit. Residues 5-9 and 124-127 of monomer A, and monomer B residues 8-9 and 124-125 of the terminal fragments were fit to the weak electron density found at the channel entrance. These poorly defined regions form the entrance to the binding domain and could be involved in the gate mechanism for the channel penetration by thyroid hormones or competitors.
Electron density corresponding to milrinone was identified deep in the binding channel and indicated that the pyridone ring is bound near the channel center and the non-substituted pyridine ring forms interactions closer to the channel entrance (Fig. 3) . The distribution of electron density reflects the 2-fold symmetry of the channel. The occupancy of 50% was imposed to reflect the discrepancy between the 2-fold symmetry of TTR binding site and the lack of such molecular symmetry of milrinone. Although no discrete density is observed at the 4-keto position (Fig. 3) , its B value is 23.2, similar to that of all the surrounding atoms. The conformation of milrinone, as measured by the torsion angle (C2-C1-Cl'-c2' = 60"), is similar to that reported for its crystal structure (ie. 42 and 52" in two determinations) (29) .
Milrinone is bound in the hydrophobic cleft formed by the side chains of Leu-17, Ala-108, Leu-110, and Thr-119 of the 2-fold-related TTR subunits (Fig. 4) . The pyridone ring is involved in extensive hydrophobic interactions with surrounding side chain methyl and methylene groups, with distances varying from 2.6 to 3.9 (2) A (Table 11 ). The cyano nitrogen (N52) forms a series of contacts with residues Leu-110, Ser-117, and Thr-118 along one side of the channel surface. On the opposite side of the channel, the closest 2-methyl substituent (C21) contact is to CB of Leu-110 of the symmetry-related TTR monomer. The pyridone ring N (3) forms a 3.8 (2) A contact to Leu-110. At the channel center, the keto group (04) is hydrogen bonded to a pair of Ser-117 side chain hydroxyl groups from both protein monomers, stabilizing the position of the molecule in the binding site (Fig. 4) . The nonsubstituted pyridine ring is positioned close to the channel 2-fold axis between two side chains of Ala-108 of the 2-fold-related monomers, similar to that reported for the 3,3'-T2 tyrosyl ring. The hydrophobic interactions with residues 108, 110, and 119 complete the binding pattern. In this position along the channel axis, the pyridine N(4') forms strong polar interactions with Lys-15 from both monomers.
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DISCUSSION
In order to understand the thyromimetic activity of milrinone and its competitive binding to transthyretin, the structure of its TTR complex was compared with those of 3,3'-T2 (22) and T g (21) . As shown in Fig. 4 , milrinone is positioned deeper in the hormone binding site than T4, and is similar to that observed for 3,3'-T2. In this structure, the pyridone ring is oriented along the channel axis, and the 4-keto and 5-cyano groups mimic the interactions of the 4"hydroxy and 3'-iodine of 3,3'-T2 occupying similar regions between p-strands. In addition, the cyano group penetrates deeper into the cleft than iodine, and thus binds closer to the protein surface than 3,3'-T2 (Fig. 5) . The 2-methyl of milrinone occupies a hydrophobic space between the side chains of Ala-108 and Thr-119 (Fig. 3) .
The weaker binding of milrinone, compared to that of thyroxine, could be attributed to the lack of polar interactions with the charged residues near the channel entrance, as observed for the alanyl side chain of T4. Its tighter binding compared to 3,3'-T2 (>60%), could be related to its stronger hydrophobic interactions with the binding site surface and its different orientation in the binding channel, as the molecule lies closer to the surface than 3,3'-T2 (Fig. 5 ) .
To understand the differences in binding affinity between milrinone and amrinone, a weaker inhibitor, modeling studies of amrinone binding interactions in the TTR binding site were Carrie$ out based on analysis of possible interactions within 3.8 A of the bound molecule in two different positions.
When amrinone was positioned as milrinone (model l), the hydrophilic 5-amino group participates in much weaker interactions with the hydrophobic binding pocket compared to the cyano group (Table 11 ). In the second orientation, model 2 ( Fig. 6) , amrinone was manually positioned closer to the channel surface so that its pyridone ring was positioned deeper in the cleft between the strand fragments of residues 108-110 and 117-119. Intermolecular contacts were monitored to guide the modeling. In this position, the polar interactions of the 5-amino, 4-keto, and N3 were strengthened (Table 11 ). However, the network of hydrophobic interactions with the surrounding surface were substantially weakened as the molecule no longer can form simultaneous contacts to both monomers. These less favorable interactions may result in its weaker binding affinity, compared to milrinone which is positioned along the 2-fold axis.
CONCLUSIONS
The positive inotropic bipyridine cardioactive agent milrinone is a strong competitive inhibitor of T4 binding to transthyretin and structural data for its TTR complex reveal that it binds with its pyridone ring deep in the hormone channel, similar to that observed for the hormone metabolite 3,3'-diiodothyronine. In this crystal complex, the 5-cyano group forms contacts analogous to the 3'-iodine of 3,3'-T2 and, as the 4'-hydroxy of 3,3'-Tz, the 4-keto group interacts with the hydroxyls of the 2-fold related Ser-117 at the channel center. These extensive interactions may explain its effectiveness as a T4 competitor, having about 60% the binding affinity of thyroxine. Modeling studies of amrinone, the 5-amino-bipyridine parent inotropic drug, reveal that its 5-amino group cannot participate in hydrophobic interactions similar to the 5-cyano of milrinone or the hormone phenolic iodine, and thus may explain its noncompetitive binding to transthyretin.
These studies offer insight into the differential action of milrinone and amrinone on the thyroid hormone transport protein and indicate that the structural homology of the 5-cyano functional group on the pyridone ring may also be exploited in their Ca2+-ATPase enzyme activation and bone resorption activity. These characteristics are apparently not crucial to their phosphodiesterase enzyme interactions as both milrinone and amrinone have comparable activities.
